Compare Celgen Biopharmaceuticals vs Serentis
Customers evaluate the quality of Celgen Biopharmaceuticals's products using the following success metrics.
Overview
Celgen Biopharmaceuticals is based in China
Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.
Serentis is based in United Kingdom
Serentis is a biopharmaceutical company which aims to develop a pipeline of products to address unmet medical needs in the dermatology field. The company's strategy is to establish a clinical stage development pipeline by the reprofiling of existing drugs and through the licensing or acquisition of projects from external sources. This is an approach that Serentis' management team has successfully pursued in the past.
Demo Video
Investors
China-Israel Value Capital
Novo Holdings, MVM Partners
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Celgen Biopharmaceuticals has not claimed their profile.
Work for Celgen Biopharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Celgen Biopharmaceuticals?
Claim your profile now.
Information not available because Serentis has not claimed their profile.
Work for Serentis? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Serentis?
Claim your profile now.